Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Glioma
- Sponsor
- National Institute of Biology, Slovenia
- Enrollment
- 16
- Locations
- 3
- Primary Endpoint
- Transcriptome profile of CD4+ T and CD56+ NK cells
- Last Updated
- 14 years ago
Overview
Brief Summary
Study on glioma patients treated with brain surgery is focusing on the analysis of their transcriptome expression profile measured in two immune cell populations, CD4+ T cells and CD56+ NK cells. The results of analysis will be compared to the reference data of healthy population. Furthermore, the metabolomic and immunological status will also be monitored and compared to healthy group reference data, before and after the surgery*. With comparative crossomics analysis the investigators intend to possibly identify new diagnostic and prognostic biological markers for the relapse of the disease. The results are expected to convey a deeper insight into pathophysiology of the glioma as well as into the mechanisms of the current surgical therapy.
* The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).
Investigators
Tamara Lah Turnsek
Director of the National Institute of Biology, Slovenia
National Institute of Biology, Slovenia
Eligibility Criteria
Inclusion Criteria
- •malignant glioma = glioblastoma (WHO IV) patients
Exclusion Criteria
- •pregnancy
- •metastases
Outcomes
Primary Outcomes
Transcriptome profile of CD4+ T and CD56+ NK cells
Time Frame: within 10 days after surgery
Secondary Outcomes
- Proteomic analysis of blood plasma samples(within 10 days before surgery, one day after surgery and once more within 10 days after surgery)
- Lymphocyte subpopulation assessment in peripheral blood samples(within 10 days before surgery, one day after surgery and once more within 10 days after surgery)
- Metabolite profiling in blood plasma samples(within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery)
- Antibody profiling in blood plasma samples(within 10 days before surgery, one day after surgery and once more within 10 days after surgery)
- miRNA profiling in blood plasma samples(within 10 days before surgery, one day after surgery and once more within 10 days after surgery surgery)